Figitumumab (previously CP-751871) is a monoclonal antibody targeting the insulin-like growth factor-1 receptor being investigated for the treatment of various types of cancer for example adrenocortical carcinoma and non-small cell lung cancer (NSCLC).This drug is being developed by Pfizer.
This page contains content from the copyrighted Wikipedia article "Figitumumab"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.